Skip to main content

Table 4 Retention of HIVIS-03 trial volunteers

From: Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/II HIVIS 03 trial

Volunteers who were: Total Males Females p-value*
  n (%) n (%) n (%)  
Randomized 79 57 22  
Exited after Randomization 19 (24.1%) 12 (21.1%) 7 (31.8%) 0.32
Enrolled 60 45 15  
Vaccination Visits     
Received 1st DNA/Placebo 60 (100%) 45 (100%) 15 (100%) -
Received 2nd DNA/Placebo 60 (100%) 45 (100%) 15 (100%) -
Received 3rd DNA/Placebo 59 (98.3%) 44 (97.8%) 15 (100%) 0.99
Received 1st MVA/Placebo 50 (83.3%) 41 (91.1%) 9 (60%) 0.02
Received 2nd MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
Safety and Immunogenicity visits     
2 weeks post 2nd DNA/Placebo 60 (100%) 45 (100%) 15 (100%) -
2 weeks post 3rd DNA/Placebo 59 (98.3%) 44 (97.8%) 15 (100%) 0.99
2 weeks post 1st MVA/Placebo 50 (83.3%) 41 (91.1%) 9 (60%) 0.02
8 weeks post 1st MVA/Placebo 50 (83.3%) 41 (91.1%) 9 (60%) 0.02
24 weeks post 1st MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
2 weeks post 2nd MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
4 weeks post 2nd MVA/Placebo 42 (70%) 37 (82.2%) 5 (33.3%) 0.002
24 weeks post 2nd MVA/Placebo 40 (66.7%) 35 (77.8%) 5 (33.3%) 0.002
  1. *p-values from Chi square or Fisher’s exact test.